We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Panel Voices Support for GSK, Valeant Seizure Drug Potiga
Panel Voices Support for GSK, Valeant Seizure Drug Potiga
August 13, 2010
An FDA advisory panel expressed support for GlaxoSmithKline (GSK) and Valeant Pharmaceuticals’ add-on seizure treatment Potiga, voting that patients can be monitored for urinary retention, which the FDA had identified as the main safety concern.